<International Circulation>: The COMPARE trial was recently published and we would like to know what you think that we have learned from this all-comers trial?

Prof. Smits: As you mentioned， it is an all-comers trial and it reflects real world conditions， which is important for clinicians， and it showed that we now have a drug-eluting stent available that has not improved safety but also efficacy. This is the first time in a drug-eluting stent trial where it was shown that we can improve both safety and efficacy.